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Title: What do patients need to know? A study to assess patients’ satisfaction with 
information about medicines.  
 
Abstract 
Objectives This study aimed to determine the information needs and reported adherence of 
patients prescribed medicines for chronic conditions in those who have received a 
community pharmacy advanced service and those who have not. 
Methods A questionnaire was constructed using validated tools to measure medication 
information satisfaction and adherence together with questions eliciting information 
regarding the use of pharmacy services and demographic characteristics. This questionaire 
was distributed from four community pharmacies to a convenience sample of 400 patients as 
they collected their medicines. Patients were eligible if prescribed more than one regular 
medicine and attending the pharmacy for longer than three months. The questionnaire was 
returned directly to the university.  
Key Findings 232 (58%) questionnaires were returned. All respondents desired further 
information about their prescribed medicines, particularly about potential medication 
problems. Dissatisfaction centred on side effects, interactions and certain medicine 
characteristics such as how long it will take to act. Satisfaction with information about 
medicines and adherence were significantly greater in a subgroup reporting that they had 
received an advanced pharmacy service e.g. medicine use review.   
Conclusion Patients who had received an advanced service reported greater adherence 
and satisfaction with medicine related information. This was a small, observational study, 
using a convenience sample of four pharmacies; in order to draw definitive conclusions, a 
larger study with participants randomised to receive an advanced service is required.  
 
Introduction 
The World Health Organisation has stated that patients not-adhering to prescribed 
recommendations for medicines for chronic conditions can lead to poor outcomes and 
increased medicines wastage and health resource utilisation(1). Reasons for non-adherence 
are often subcategorised into intentional and unintentional causes(2). Unintentional non-
adherence occurs when practical barriers such as poor dexterity or memory impair the 
individual’s ability to take their medicines as prescribed. Intentional non-adherence occurs 
when perceptual barriers such as beliefs, concerns and expectations lead a patient to make 
a conscious decision to deviate from the prescriber’s recommendations. Often patient 
behaviour is an amalgam of unintentional and intentional factors and thus current adherence 
research is largely focussed on complex interventions to target both practical and perceptual 
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barriers.(3) Conversely, routine healthcare provision is dominated by practical behaviour 
change techniques such as simplifying dosage regimens and providing adherence aids or 
education(4) which have demonstrated marginal adherence enhancing effects.(5)  
 
A positive relationship between patient satisfaction with information received and adherence 
is, however, consistently reported.(6) The Satisfaction with Information about Medicines 
Scale(6) acknowledges that patients have differing information needs; some patients with an 
internal locus of control and thus a belief that their own actions can influence the 
outcomes from their prescribed medication may desire detailed information regarding 
their prescribed medicine whilst others in response to detailed information may feel 
distressed and adopt coping strategies e.g. making a conscious decision not to take the 
medicine  resulting in reduced adherence.(7)  
 
An essential component of United Kingdom community pharmacy services is provision of the 
medicines related information necessary for a patient to adhere to their prescribed medicine. 
In 2005, the UK government introduced two advanced community pharmacy services to 
support patient adherence by providing appropriate patient information regarding medicines. 
These services, termed medicine use review (MUR) and new medicines service (NMS), 
include information provision and adherence assessment as key elements and guide 
practitioners to ask whether the patient is experiencing any problems or concerns with taking 
their medicines. There is, however, no comprehensive training or guidance for  pharmacists 
regarding how such problems might be effectively addressed and therefore this may be 
leading to a one-size-fits-all approach to conducting services with many pharmacists 
conducting reviews on patients that may not require them and providing information that the 
patient does not require (8-11). Some MUR studies have demonstrated a positive impact on 
medicines knowledge, patient confidence and an improvement in disease outcomes.(12-17). 
There has, however, been criticism of both the MUR and NMS from within pharmacy and 
other professional groups such as general practitioners regarding the extent to which they 
successfully support patient medication adherence.(8-10, 18, 19) In particular there is 
evidence to show that pharmacists may be conducting MURs simply to achieve targets set 
by the companies which they work for, rather than based on patient need (11, 18, 20).  
 
An exploration of patient satisfaction with medicines related information received, adherence 
and whether any variation exists between patients who have and have not received an 
advanced service may provide greater clarity regarding the extent to which essential and 
advanced community pharmacy services are fulfilling the needs of patients. Therefore, the 
3 
 
aim of this study is to determine the information needs and reported adherence of patients 
prescribed medicines for chronic conditions in those who have received a community 
pharmacy advanced service and those who have not.An additional objective of the study is 
to explore the relationship between adherence and information satisfaction.  
 
Method 
Ethical approval for this final year pharmacy student project was obtained from the University 
of East Anglia Faculty of Medicines and Health Research Ethics Committee. 
 
A convenience sample of five community pharmacies (three independents and two 
supermarkets) was invited using email with a follow-up phone call to ascertain willingness to 
participate. All pharmacies expressed an interest in participation and were visited, the study 
requirements described and verbal consent obtained from the pharmacy manager.  
 
During an eight week period, staff employed by each participating pharmacy identified all 
patients attending the pharmacy whilst the student was present if they met the following 
criteria: prescribed more than one regular medicine for a long term condition (similar criteria 
to the MUR service), aged 18 years or over and receiving medication dispensed by the 
pharmacy for at least three months. Pharmacy staff approached all eligible patients to avoid 
selection bias, briefly introduced the survey and indicated the recruiting student’s presence. 
Patients expressing an interest in participation approached the student who provided further 
information about the service evaluation, a patient information leaflet, questionnaire and 
envelope for pre-paid return to the university. A complementary pen was provided to 
enhance the likelihood of response(21). Patients were able to complete the questionnaire in 
the pharmacy or take it home to complete at a later date. Consent was assumed from return 
of a completed questionnaire either by post or in person.  
 
The questionnaire comprised the validated Satisfaction with Information about Medicines 
Scale (SIMS) (6) and Morisky Measure of Adherence Score (MMAS-4) (22) to explore the 
primary outcomes together with questions to describe respondent demographic 
characteristics and use of pharmacy services.  
 
The 17 item SIMS invites patients to rate the information received regarding their prescribed 
medicines. It was validated in patients receiving more than one medicine for more than two 
months for a variety of chronic conditions. It was chosen as this closely matches the MUR 
inclusion criteria and is focused on the level of satisfaction with regard to different aspects of 
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information about medicines. The tool contains two categories: the first nine questions relate 
to medicine’s actions and usage e.g. what the medicine is for and how long it takes to work,  
whilst questions 10 to 17 examine potential problems with the medicine e.g. the likelihood of 
experiencing side effects and what to do if a patient misses a dose. The options of the 
information received being “about right” or “none needed” are assigned a score of 1 and “too 
much”, “too little” or “none received” is scored as 0. Scores therefore range from 0-17 with 
higher scores indicating greater satisfaction. (6) 
 
The MMAS-4(23) comprises four ‘yes’/’no’ questions generating a score of one to four, 
where a score of four indicates self-reported full adherence and scores of one to three 
signify partial adherence. Both questionnaires ask patients to reflect on information provided 
for all of their medicines.  
 
The patient information leaflet and questionnaire comprised a brief description of MUR and 
NMS. Respondents were then asked whether they had received an MUR or NMS in the 
previous year and space was provided for any thoughts on the services. Space was also 
provided for any further comments or thoughts.  
 
Piloting (which took place in a separate pharmacy from those in the main study) with 20 
patients yielded a low response rate of 45% so the questionnaire information was amended 
to further emphasise that respondents are anonymous, in line with the literature (24).  
 
In the main study, a target of 100 recruited patients per pharmacy was set. Recruiting 
students each attended one of the four pharmacies for consecutive full days (9am-6pm) until 
100 patients had been recruited. This was a convenience sample with a target number of 
patients to approach that would be achievable within the timespan of the project whilst 
providing the evaluation with enough data to draw sensible conclusions.  
 
Descriptive statistics were used to report the demographic data. SIMS was analysed both as 
a score out of 17 and as the two subscales; these data were reported as a mean (95% 
confidence interval) or median (interquartile) as appropriate depending upon whether the 
data were normally distributed or skewed respectively. MMAS-4 scores were dichotomised 
into ‘adherent’ and ‘partially adherent’. Logistic regression analysis was used to examine 
whether receipt of an advanced service was associated with self-reported adherence. The 
following factors directly related to experience of the advanced service: pharmacy service 
provider, frequency of access to the pharmacist and SIMS score were also included as 
independent variables. The choice of dichotomisation for SIMS Action Usage and SIMS 
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Potential Problem was based on exploratory data analysis which revealed a clear change-
point or jump in the relationship between the log-OR and SIMS scores. The choice of cut-
point was based on visual inspection of when the adherence rate changed greatly between 
two SIMS scores. A simple content analysis was performed on the ‘additional comments’ 
responses. All tests were carried out at the 5% level of significance. 
 
Results 
One pharmacy was recruited for the pilot and four separate pharmacies (two independent 
and two multiples/chains) were recruited for the main study. Four hundred patients were 
recruited from four community pharmacies in Norfolk, UK. A total of 265 questionnaires 
(66.3%) were returned, of which 33 (12%) were excluded from analyses because 
respondents reported that they received only one regular medicine, yielding an actual 
response rate of 232/367 (63.2%). The questionnaires were primarily returned by post with 
only 38 (16.4%) respondents completing the questionnaire in the pharmacy. Of the 232 
repondents prescribed more than one medicine, 118 (50.9%) reported receiving an 
advanced service with 105 (45.3%) reporting an MUR and 51 (22%) an NMS intervention. 
Eleven (4.2%) respondents were unsure about whether or not they had received an 
advanced service and were thus excluded from the analysis comparing advanced service 
provision. For respondents reporting not having received an advanced service, the mean 
(SD) age was 65.24 (15.59) years of which 55 (48.2%) were male, 50 (43.9%) respondents 
reported visiting a pharmacy once per month and 38 (33.3%) visited more than once per 
month. 57 (50%) of respondents reported taking more than five medicines. For respondents 
reporting receipt of an advanced service, the mean (SD) age was 65.65 (12.89) years of 
which 54 (45.8%) were male. A pharmacy visit once per month was reported by 59 (50%) 
respondents and more than once per month by 37 (31.4%) respondents which is 
comparable to respondents who reported not receiving an advanced service. 53 (44.9%) 
respondents reported taking more than five medicines.  
 
Table 1 and figures 1 and 2 provide a comparison of the SIMS scores for respondents 
reporting receipt of an advanced service compared with no advanced service. Most 
respondents were satisified with information received relating to the action and usage of 
medicines. Notable exceptions were ‘How you can tell if it is working’ and ‘How long it will 
take to act’. There was, however, a widespread desire for further information regarding the 
potential problems of their medicines.  
 
Insert Figure 1 and 2 
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The MMAS-4 was completed by 229 respondents of whom 125 (54.6%) reported that they 
were adherent. Table 2 summarises the relationships of potential factors associated with 
MMAS-4 reported adherence.  
 
Insert Table 2 
Receipt of an advanced service doubled the likelihood of adherence. No association was 
identified between adherence and the pharmacy providing services or frequency of 
pharmacy visits. 
 
A non-linear relationship was observed from exploratory analysis of SIMS and MMAS-4 
which revealed a sudden jump in odds at certain scores of SIMS. SIMS 'action and usage' 
was therefore grouped into scores of 0 to 8 and scores of 9 whilst SIMS ‘potential problems’ 
was grouped into scores of 0 to 6, and 7 to 8. The adjusted odds ratio from the logistic 
regression model showed that the odds of being adherent were marginally higher for 
participants reporting a high level of 'action and usage' satisfaction but not significantly 
related to SIMS 'potential problems'. However, there was significant interaction between the 
terms; participants reporting a high level of satisfaction for both ‘action and usage’ and 
‘potential problems’ information items were over six times more likely to be adherent.  
 
Analysis of respondent comments identified a general endorsement of the advanced 
services. Respondents who had received one of the advanced services largely felt that it had 
served to reassure them about their medication. 
 
“was reassured about my concerns and questions by the pharmacist, no such talks with GP. 
I always approach a pharmacist now as I am confident in their approach” (223B, male) 
 
Some respondents highlighted that it was useful to reinforce advice that had been given by 
the GP or to seek information that had not been obtained during the GP consultation. 
 
“It would help to reinforce what the Dr has told you, especially on side effects.” (349B, 
female) 
 
“very useful as questions come up after you leave doctors and you can then ask pharmacist” 
(201B, female) 
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Two respondents noted that the information received from the pharmacist had seemed 
“rushed” and one person stated that the consultation had been performed “at one side of the 
counter”. 
 
There were some respondents for whom the service was either not appropriate or not 
deemed to not fit in to their medical care. 
“as I understand my medication I didn't really need this facility but I'm sure it is useful for 
many people” (218B, female) 
 
This respondent is acknowledging that whilst not personally required, the service may have 
a benefit for other people.  
 
“neither services will be of interest to me as this is something my doctor and I review 
regularly. I don't think I would want to review this with a pharmacist anyway” (228B, female) 
 
This comment suggests that the respondent already receives her information from another 
source and therefore she is questioning the usefulness of a duplicate service from a 
healthcare professional perceived to be less appropriate for the purpose.  
 
Discussion 
Patients who had received an advanced service reported greater adherence and satisfaction 
with medicine related information, however there were still needs for information in both 
groups. In general, patients appear to be largely satisfied with the information received about 
their prescribed medicines with no variation across different pharmacies or the frequency of 
visits. A desire for further information about what can be expected from a medicine in terms 
of how quickly it might work, how to identify efficacy and potential problems associated with 
prescribed medicines was demonstrated. Whilst it is not possible to demonstrate a causal 
link due to the observational nature of the study, the evidence supports the assumption that 
adequate information regarding the potential problems of a medicine is necessary in addition 
to the basic actions and usage of a medicine in order to achieve adherence. Pharmacists 
should therefore ensure that discussions with patients address information relating to side 
effects (including the risk of experiencing them), interactions with other medicines, what to 
do if a dose is missed, length of time taken to have an effect and how a patient can tell if the 
medicine is working.  
 
The strengths of this study are the high response rate, wide ranging demographic 
characteristics of respondents and generally well completed questionnaires. Furthermore, 
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the inclusive eligibility criteria reflecting those of MURs service provision support the 
relevance of this evaluation. However, the study comprised a small number of pharmacies 
situated within a geographically confined area which limits generalisability. By only including 
patients taking more than one medicine for a chronic condition, this evaluation may have 
excluded patients that had received the new medicine service and were currently prescribed 
no additional medicines.  
 
Further study design limitations are response bias introduced by the willingness to please of 
regular pharmacy patients and selection bias of responders who may be more adherent to 
their medicines and more active in healthcare decision making than non-responders. To 
mitigate these effects, potential participants were informed that the questionnaire would be 
returned to the university and that the pharmacist would not see their responses. The 
protocol was designed to minimise recruitment bias by pharmacy staff, however, protocol 
fidelity could not be determined as the research team had no access to pharmacy records in 
order to confirm that all potential participants had been approached. A further study limitation 
was the lack of data collected on those patients who were approached to participate and 
either didn’t agree to speak to the student or didn’t complete the questionnaire. This data 
would have allowed a comparison to be made to determine the representativeness of the 
sample and inform the generalisability of the conclusions.  
 
Finally, self-reported adherence has been shown to have lower specificity compared to pill 
counts or electronic monitoring(25, 26). Conversely, the reactive bias of the latter measures 
and higher costs mean that there is yet to be an accepted gold standard measure of 
adherence.(27)   
 
The present study has demonstrated that information provision regarding action and usage 
of medicines is largely satisfactory excepting ‘how long it will take to act’ and ‘how to tell if it 
is working’. Addressing issues related to the potential problems of medicines was frequently 
perceived as deficient with greater satisfaction predicting greater adherence. These pieces 
of information are particularly pertinent to the context of preventing intentional non-
adherence by managing patient expectations of their medicine both in terms of side effects 
and efficacy. Even respondents who had received an advanced service identified these 
aspects of information as frequently suboptimal. A similar investigation of information 
satisfaction, in a sample of 140 in-patients, found that the medication’s effect on sex life and 
the risk of getting side effects were the two lowest scoring items(28). Further studies have 
also confirmed that information provision about medicines may be inadequate.(29, 30)  
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The significantly greater satisfaction with information about potential problems in patients 
who have received an advanced pharmacy service suggests that the MUR and NMS 
interventions may help in addressing some patient concerns. It may also support previous 
research demonstrating that MURs enhance knowledge and understanding of medicines(16, 
17). However, the present study findings also indicate that MUR and NMS consultations are 
not addressing all of the patient’s needs for information about their medicines. Recent work 
has shown that pharmacy services should take account of patients’ perceptions of their 
illness (31) and this evaluation suggests that this should extend to their knowledge and 
beliefs about their medication.  
 
The high completion rate of the SIMS suggests that it may be acceptable to use in routine 
practice to target patients in most need of an advanced service. If patients were aware of the 
information they were lacking it may prompt them to ask their pharmacist for advice. Such 
patients may also speak with their doctor who could refer the patient to the pharmacist. If the 
doctor was to refer patients to the pharmacist then patients may perceive the pharmacist’s 
consultation as a more integrated part of the health service. This would also align with the 
comments, from respondents, about the services and the likelihood they would engage with 
them. Some identified that they had no need for the services as they already received 
information from their GP. These results concur with findings from a series of focus groups 
conducted in patients with diabetes (32). Previous work suggests that patients have opinions 
regarding the suitability of each healthcare professional for providing information and their 
relationship with those professionals is central to determining where they obtain it.  
 
It cannot be assumed that the improvement in adherence is resultant of the MUR or NMS 
service. The greater proportion of self-reported adherence in the MUR group may be 
attributable to willingness to please of the patient or a selection bias introduced by whom 
pharmacists invite for an MUR. Although patients who had received an MUR were more 
satisfied with information, it was not established how satisfied patients were before receipt of 
the services so it cannot be conclusively stated that the service was responsible for the 
increased satisfaction.  
 
There is therefore a clear need to more effectively target advanced services, particularly 
MURs, at those patients that need and, in particular, want them. This study provides an 
indication of the subjects of interest to patients that may be addressed as part of the MUR or 
NMS.  
 
Conclusion 
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This study indicates the types of information that patients who take regular medicines may 
be lacking. These largely relate to the potential problems of medicines rather than their 
action and usage. The SIMS may be an appropriate tool to identify which patients may 
benefit from a community pharmacy advanced service. Despite being more satisfied with 
information received about medicines, the respondents who had received an advanced 
service had unaddressed medication information needs. This may imply that detailed, 
comprehensive information about potential problems should be provided during MUR and 
NMS consultations in addition to the actions and usage of medications. 
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Table 1: comparison of SIMS score between those patients in receipt of an advanced 
service and those without. 
 
SIMS 
component 
Measure Advanced 
service 
No advanced 
service 
p-value# 
Overall Median (IQ) 14 (10-17) 12 (7-16) 0.001 
Action and usage Median (IQ) 8 (6-9) 7 (5-9) 0.002 
Potential 
problems 
Median (IQ) 7 (4-8) 4 (2-7) <0.001 
#MWU; N=208  
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Figure 1 Scores for action and usage subscale of SIMS for those that have and have 
not received an advanced service   
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Figure 2 Score for the potential problems subscale of SIMS for those that have and 
have not received an advanced service  
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Table 2: Association between factors and self-reported adherence 
Factor Partially adherent 
(n=104) 
Adherent 
(n=125) 
Univaria
te p-
value 
Adjusted OR (95% CI)3 Adjuste
d p-
value3 
Pharmacy providing the service 0.0861  
Pharmacy 1 19 39 (67.2) 1.81 (0.75,4.37) 0.19 
Pharmacy 2 27 29 (51.8) 0.94 (0.38,2.3) 0.889 
Pharmacy 3 27 33 (55.0) 1.62 (0.7,3.78) 0.263 
Pharmacy 4 31 24 (43.6) 1 N/A 
Pharmacy visit frequency 0.2451  
<once per month 39 34 (46.6) 1 N/A 
Once per month 46 63 (57.8) 1.54 (0.77,3.1) 0.226 
>once per month 19 28 (59.6) 1.91 (0.8,4.55) 0.143 
Self-reported receipt of advanced service 0.0011  
No 63 48 (34.8) 1 N/A 
Yes 41 77 (65.3) 2.34 (1.21,4.53) 0.012 
SIMS ‘action and usage (median/IQR) 7 (5-9) 9 (6-9) 0.00632  
SIMS ‘action and usage’ group <0.0011 
0-8 73  55 (42.97)  1  
9 29 63 (68.48)  1.04 (0.32,3.44) 0.946 
SIMS ‘potential problems’ (median/IQR) 5 (3-7) 7 (3-8) 0.0092  
SIMS ‘potential problems’ group 0.001  
0-6 65 53 (44.9) 1  
7-8 30 63 (67.7) 0.48 (0.14,1.6) 0.232 
Interaction between SIMS 'potential problems' and 'action 
and usage' 
NA NA  6.82 (1.2,38.56) 0.03 
1 Chi-squared/Fisher’s exact test; 2 Wilcoxon Rank-sum test; 3 Based on a multivariable logistic regression model adjusting for all other factors 
in the table. 
 
